Metabolic

Retatrutide

Triple Agonist Peptide

Also referred to as LY3437943.

Retatrutide is a synthetic triple-receptor agonist peptide — also designated LY3437943 — that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR) receptors. It is an investigational compound and has not received regulatory approval for clinical use.

The published evidence base includes phase 1 through phase 3 human trials, with research examining the compound primarily in the context of obesity, type 2 diabetes, metabolic liver disease, and related complications.

Published on Retatrutide

Research OverviewRetatrutide Peptide: Mechanism of Action ExplainedRetatrutide is a synthetic triple hormone receptor agonist peptide — also designated LY3437943 — engineered to simultaneously activate three metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).